Clinical Trial Detail

NCT ID NCT04264806
Title A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

chronic myelomonocytic leukemia

myelodysplastic syndrome

Therapies

ARGX-110 + Azacitidine

Azacitidine

Age Groups: adult senior

No variant requirements are available.